Magee-Womens Hospital
Pittsburgh, Pennsylvania, 15213, United States
NCT Number: NCT01540396
This is a pilot feasibility study of 40 pregnant women to test the investigators' recruitment, enrollment and randomization procedures in preparation to conduct a larger randomized control trial to compare diagnostic methods for gestational diabetes. The two methods that are being compared are the 2 hour 75 gram OGGT (2011 ADA guidelines) versus a 1 hour 50 gram GCT + 3 hour 100 gram OGTT if the 1 hour result is abnormal (Carpenter and Coustan criteria).
Looking for future studies?
Notify Me18 year–50 year
Female
Interventional
Not applicable
Pittsburgh, Pennsylvania, 15213, United States
This is a pilot feasibility study of 40 pregnant women between 24-28 weeks gestation to test the investigators recruitment, enrollment and randomization procedures in preparation to conduct a larger randomized control trial to compare diagnostic methods for gestational diabetes.
Forty women 18 years of age or older will be recruited at 20-24 weeks pregnancy from the ob/gyn outpatient practices at Magee-Women's hospital (MWH). Eligible women will return to MWH main lab between 24-28 weeks gestation for the routine 1 hour 50gm glucose challenge test. Women with blood glucose values less than 200 will be randomized to receive either the fasting 2 hour 75 gm oral glucose tolerance test (OGTT)or the 3 hour 100 gm OGGT within two weeks. Gestational diabetes will be determined for the 2 hour 75 gm OGGT arm based on the 2011 ADA guidelines and the 3 hour 100 gm OGGT arm based on the Carpenter and Coustan criteria. Patients and their providers will be informed of the diagnosis of gestational diabetes, but they will be blinded to the criteria used to make the diagnosis as well as the specific results of glucose tolerance testing.
Chart reviews will be conducted to assess for perinatal maternal and infant health factors (e.g.pregnancy weight, gestational weight gain, co morbidities) as well as for data on perinatal outcomes related to GDM such as macrosomia, c-sections, and birth trauma. Two brief self-administered questionnaire will assess participants' views on screening for gestational diabetes and assess participants experience with and solicit feedback on the study procedures.
At the end of this pilot study, the investigators will have experience with recruitment, retention, and randomization procedures and have made the necessary protocol revisions. If successful, this feasibility study will provide the preliminary data and feasibility justification needed to conduct a larger randomized control trial to compare the effectiveness of two diagnostic methods for gestational diabetes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.
Time frame: Will be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)
Defined as birthweight >90th percentile for gestational age or birthweight >4000 grams
Time frame: Will be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)
Primary or repeat cesarean delivery
Time frame: Will be followed from study enrollment until delivery (approximately 40 weeks' gestation)
Assess how frequently a diagnosis of gestational diabetes is made
Time frame: Will be assessed from study enrollment until 30 days after delivery
New onset hypertension +/- proteinuria
Time frame: First 24 hours of life
Defined as blood glucose less than 80 mg/dL from heel stick within 1 hour after delivery
Time frame: First 7 days of life
Defined as bilirubin greater than 5 mg/dL over 24 hours from heel stick
Time frame: Will be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)
Defined as shoulder dystocia/brachial plexus injuries
Time frame: Will be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)
3rd or 4th degree perineal laceration or postpartum hemorrhage
University of Pittsburgh
Other
GD2M Study:Gestational Diabetes Diagnostic Methods
Acronym: GD2M
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07336914
Diabetes Mellitus, Diabetes, Gestational
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial DetailsNCT06127823
Diabetes Mellitus, Diabetes, Gestational
Herlev, Denmark
View Trial DetailsNCT04724330
Body Weight, Body Weight Changes
Baltimore, Maryland, United States
View Trial DetailsNCT06556927
Anxiety, Anxiety Disorders
Kırklareli, Turkey (Türkiye)
View Trial Details